An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Trial Profile

An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Omaveloxolone (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Acronyms DISCOVER
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 28 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 24 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top